Related references
Note: Only part of the references are listed.Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?
E. Galmozzi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Review article: genetic factors that modify the outcome of viral hepatitis
A. F. Staettermayer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
BASIC AND TRANSLATIONAL-LIVER
Robert E. Lanford et al.
GASTROENTEROLOGY (2013)
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B
Pietro Lampertico et al.
HEPATOLOGY (2013)
Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype
Milan J. Sonneveld et al.
HEPATOLOGY (2013)
A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice
Pascale Buchmann et al.
VACCINE (2013)
Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese
Xiaopan Wu et al.
ANTIVIRAL RESEARCH (2012)
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype
Milan J. Sonneveld et al.
ANTIVIRAL THERAPY (2012)
Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B
Milan J. Sonneveld et al.
GASTROENTEROLOGY (2012)
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
Milan J. Sonneveld et al.
HEPATOLOGY (2012)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
George Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2012)
An integrated map of genetic variation from 1,092 human genomes
David M. Altshuler et al.
NATURE (2012)
A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers
Johannes Vermehren et al.
PLOS ONE (2012)
Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean
Nao Nishida et al.
PLOS ONE (2012)
Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?
V. Rijckborst et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy
Tai-Chung Tseng et al.
ANTIVIRAL THERAPY (2011)
Strong Influence of Human Leukocyte Antigen (HLA)-DP Gene Variants on Development of Persistent Chronic Hepatitis B Virus Carriers in the Han Chinese Population
Xiuchan Guo et al.
HEPATOLOGY (2011)
A Randomized Trial of Peginterferon α-2a With or Without Ribavirin for HBeAg-Negative Chronic Hepatitis B
Vincent Rijckborst et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies
Santiago Rodriguez et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2009)
Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a
Patrick Marcellin et al.
GASTROENTEROLOGY (2009)
Chronic Hepatitis B: Update 2009
Anna S. F. Lok et al.
HEPATOLOGY (2009)
High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study
Rami Moucari et al.
JOURNAL OF HEPATOLOGY (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians
Yoichiro Kamatani et al.
NATURE GENETICS (2009)
Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b
Erik H. C. J. Buster et al.
GASTROENTEROLOGY (2008)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
F. Bonino et al.
GUT (2007)
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
CJ Chen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised
HLA Janssen et al.
LANCET (2005)
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
M van Zonneveld et al.
HEPATOLOGY (2004)
Share Paper
